WebSideris Pharmaceuticals is a biopharmaceutical company that develops therapeutics for the treatment of transfusion-related iron overload. Use the CB Insights Platform to explore Sideris Pharmaceuticals's full profile. WebFunding. Sideris Pharmaceuticals has raised a total of $32.6M in funding over 2 rounds. Their latest funding was raised on Oct 22, 2013 from a Series A round. Sideris Pharmaceuticals is funded by 3 investors. OUP (Osage University Partners) and Hatteras Venture Partners are the most recent investors.
Did you know?
WebExplore {Sideris Pharmaceuticals's key management people. Discover current leadership team members including founders, CEO, other executives and board directors. Sideris Pharmaceuticals CEO, Founder, Key Executive Team, Board of Directors & Employees WebSideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The companys operations include facilities in Boston, MA, and in Gainesville, FL.
WebSep 22, 2024 · JLK is a consultant for Agios and Ionis Pharmaceuticals and has received research funding as a co-investigator from Novartis Pharmaceuticals Corporation, Agios Pharmaceuticals, Apopharma, Inc, and Bluebird Bio. BIJ and KP were employees in Sideris at the time of the study. GB was employee, officer, and shareholder in Sideris at the time of … WebCompany profile page for Sideris Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information
WebOct 23, 2013 · Sideris Pharmaceuticals has entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive right to acquire Sideris and its lead asset, the iron-chelating candidate SP-420. Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $300 million. Sideris … WebOct 28, 2013 · Novartis has signed a pact giving it the exclusive right to acquire Sideris Pharmaceuticals, a University of Florida spin-off, for up to $300 million. The deal is a companion to a $32 million fund ...
WebBEVERLY HILLS, Calif., April 26, 2024 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE™ protein biologic technology platform, today announced the appointment of Gregory Berk, M.D., to the …
WebHe has 30+ years of experience and has served as President of R&D and CMO of GT Biopharma, CMO of Celularity, executive roles at Verastem, Sideris Pharmaceuticals, BIND Therapeutics, Abraxis BioScience, Intellikine, and served on the integration leadership team during the Celgene acquisition of Abraxis in 2010. literacy development milestones 3-5 yearsWebJulio Vega represents public and private companies in a broad range of industries, including biotechnology, medical devices, nanotechnology, advanced materials, software, networking, e-commerce, and fintech. Julio has experience counseling clients on venture capital and other private equity financing transactions, public offerings, mergers and ... implicit bias test project implicitWebKazumi Shiosaki, Ph.D., is managing director of MPM Capital and co-founder, CEO and president of Mitobridge, Inc. She is the founder and CEO of Primera Diagnostics and Epizyme. Shiosaki was the former SVP of Drug Discovery for Millenium Pharmaceuticals, the president of Sideris Pharmaceuticals, Inc. and served as Scientific and Strategy Advisor ... implicit bias photosWebMar 17, 2024 · Brenda Jeglinski is a Head Vice President, Clinical Operations at Boston Pharmaceuticals based in Cambridge, Massachusetts. Previously, Brenda was a Clinical Operations Head at Neurogastrx and also held positions at Verastem, WAVE Life Sciences, Sideris Pharmaceuticals, Ironwood Pharmaceuticals. Brenda received a BS degree from … implicit bias police officersWebPierre Fabre Group. Jan 2016 - Jan 20246 years 1 month. Greece. Quality, Regulatory, Vigilance, Scientific & Medical Information Director. Head of Market Access. Product portfolio: medicinal products, medical devices, food supplements and cosmetics. Country responsible for local QMS, compliance. implicit bias stereotypeWebOct 23, 2013 · News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. literacy development theoriesWebSP 420 is a brain-penetrant iron chelator, being developed by Abfero Pharmaceuticals (a subsidiary of Pharmacosmos), under a license from University of Florida, SP 420 ... Developer Sideris Pharmaceuticals Class Small molecules Mechanism of Action Iron chelating agents Orphan Drug Status ... implicit bias tests debunked